Tadalafil in patients with chronic obstructive pulmonary disease: A randomised, double-blind, parallel-group, placebo-controlled trial

The Lancet Respiratory Medicine

Volumn 2, Issue 4, 2014, Pages 293-300

  Goudie, Andrew R ^a   Lipworth, Brian J ^a   Hopkinson, Pippa J ^a   Wei, Li ^a   Struthers, Allan D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TADALAFIL; CARBOLINE DERIVATIVE; PHOSPHODIESTERASE V INHIBITOR;

ABDOMINAL AORTA ANEURYSM; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; DRUG WITHDRAWAL; DYSPEPSIA; EXERCISE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TRANSIENT ISCHEMIC ATTACK; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; EXERCISE TOLERANCE; HYPERTENSION, PULMONARY; MULTICENTER STUDY; QUESTIONNAIRE; TREATMENT OUTCOME;

AGED; CARBOLINES; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; SCOTLAND; TREATMENT OUTCOME;

EID: 84897957796     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70013-X     Document Type: Article

References (30)

1. Santos S, Peinado VI, Ramírez J, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002, 19:632-638.
2. Sims MW, Margolis DJ, Localio AR, Panettieri RA, Kawut SM, Christie JD Impact of pulmonary artery pressure on exercise function in severe COPD. Chest 2009, 136:412-419.
3. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981, 36:752-758.
4. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 159:158-164.
5. Hilde JM, Skjørten I, Grotta OJ, et al. Right ventricular dysfunction and remodeling in COPD without pulmonary hypertension. J Am Coll Cardiol 2013, 62:1103-1111.
6. Christensen CC, Ryg MS, Edvardsen A, Skjønsberg OH Relationship between exercise desaturation and pulmonary haemodynamics in COPD patients. Eur Respir J 2004, 24:580-586.
7. Chaouat A, Bugnet A-S, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172:189-194.
8. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903.
9. Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010, 181:270-278.
10. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008, 32:619-628.
11. Lederer DJ, Bartels MN, Schluger NW, et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD 2012, 9:268-275.
12. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
13. Kiely DG, Cargill RI, Wheeldon NM, Coutie WJ, Lipworth BJ Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. Cardiovasc Res 1997, 33:201-208.
14. Dabestani A, Mahan G, Gardin JM, et al. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography. Am J Cardiol 1987, 59:662-668.
15. Howard LS, Grapsa J, Dawson D, et al. Echocardiographic assessment of pulmonary hypertension: standard operating procedure. Eur Respir Rev 2012, 21:239-248.
16. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117.
17. Cenedese E, Speich R, Dorschner L, et al. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 2006, 28:808-815.
18. MacIntyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005, 26:720-735.
19. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997, 155:1278-1282.
20. Criner GJ, Cordova FC, Furukawa S, et al. Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160:2018-2027.
21. Pynnaert C, Lamotte M, Naeije R Aerobic exercise capacity in COPD patients with and without pulmonary hypertension. Respir Med 2010, 104:121-126.
22. Naeije R, Boerrigter BG Pulmonary hypertension at exercise in COPD: does it matter?. Eur Respir J 2013, 41:1002-1004.
23. Francis S, Corbin J Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep 2003, 4:457-465.
24. Forgue ST, Patterson BE, Bedding AW, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006, 61:280-288.
25. Tossavainen E, Soderberg S, Gronlund C, Gonzalez M, Henein MY, Lindqvist P Pulmonary artery acceleration time in identifying pulmonary hypertension patients with raised pulmonary vascular resistance. Eur Heart J Cardiovasc Imaging 2013, 7:7.
26. Mikhail GW, Prasad SK, Li W, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 2004, 25:431-436.
27. Kitabatake A, Inoue M, Asao M, et al. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation 1983, 68:302-309.
28. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003, 167:735-740.
29. Paterson I, Michelakis ED The role of doppler echocardiography in pulmonary artery hypertension: the importance of proving the obvious. Chest 2011, 139:973-975.
30. Blanco I, Santos S, Gea J, et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J 2013, 42:982-992.